| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 70.38M | — |
| Operating expense | — | — |
| Net income | 17.05M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, LMAT returned -17.6% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +1.7% |
| 1 year | -17.6% |
| 5 years | +51.7% |
| 10 years | +390.1% |
| All-time high | $109.75 (Apr 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in LMAT would be worth today ›Yes. LeMaitre Vascular, Inc. paid 4 dividends over the past 12 months. The most recent was $0.25 per share on Aug 20, 2026. The dividend yield is 1.22%.
LeMaitre Vascular, Inc. stock trades on NASDAQ under the ticker symbol LMAT.
LeMaitre Vascular, Inc. is part of the Healthcare sector.
LeMaitre Vascular, Inc. has a market cap of 1.87B USD, based on the latest quote.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
